Global Program Clinical Head

Job Description Summary

The Global Program Clinical Head (GPCH) is the global clinical leader responsible for one or more clinical programs across indications, involving one or multiple compounds. As the leader of Global Clinical Team(s) (GCT), the GPCH is accountable for the design, implementation, and execution of a clinical development program(s) to support decision milestones, regulatory requirements, market access, and owns the risk benefit-assessment for the program(s).

The GCPH contributes to the disease area strategy and is accountable specifically for the clinical development strategy.

Are you prepared to embrace a distinctive opportunity as the Global Program Clinical Head - Immunology at Novartis?

As the overseer of Global Clinical Team(s) (GCT), you will have a vital role in creating, implementing, and carrying out clinical development programs. Your contributions will aid in crucial decision‑making, meeting regulatory standards, and ensuring market accessibility, while also allowing you to contribute to the overall strategy in the field of immunology. Join our exceptional team and make a substantial difference in this specialized area.

• The Global Program Clinical Head (GPCH) is the global clinical leader responsible for one or more clinical programs across indications, involving one or multiple compounds. As the leader of Global Clinical Team(s) (GCT), the GPCH is accountable for the design, implementation, and execution of a clinical development program(s) to support decision milestones, regulatory requirements, market access, and owns the risk benefit‑assessment for the program(s).
  
  The GCPH contributes to the disease area strategy and is accountable specifically for the clinical development strategy.
  Your responsibilities as GPCH will include the following:

• Leading the GCT and representing Clinical Development on the Global Program Team (GPT)

• May serve as the Clinical Development Representative on Novartis Institute for Biomedical Research (NI ) Translational Medicine/project teams to drive progress of early projects to Transition Decision Point (TDP), including developing the Clinical Development Plan (CDP)

• Post‑TDP, leading the execution of the CDP and contributing to the Integrated Development Plan (IDP) generated by multiple line functions, in line with the Target Product Profile (TPP), which is designed for successful global regulatory approval/market access for one or multiple treatment indications and/or multiple programs

• Leading the creation of clinical components of key documents (e.g., Clinical Trial Protocols, Investigator Brochures, Clinical Study Reports, regulatory documents including maintenance of product licenses, registration dossiers, value dossiers, pharmacoeconomic dossiers) with high quality and consistent with the CDP, IDP, and TPP. Supporting registration, market access, commercialization, and maintenance of product licenses (e.g., Core Data Sheet, Periodic Safety Update Report, clinical benefit‑risk assessment for license renewals) for the compound(s)

• Together with Patient Safety, ensuring continuous evaluation of the drug safety profile, including safety monitoring of clinical studies and signal detection from post‑marketing surveillance; serving as a core member of the Safety Management Team

• As the medical expert, leading interactions with external stakeholders (e.g., regulatory authorities, key opinion leaders, data monitoring committees, advisory boards, patient advocacy groups), internal stakeholders (e.g., NI  Research, Translational Medicine, Medical Affairs, Commercial, Portfolio & Strategy, Health Economics & Outcomes Research), and internal decision boards

• MD or equivalent (preferred), PhD, or Pharm
  
  D degree required, with equivalent experience also considered. Specialization in a subspecialty may be needed.

• Board certified in Immunological Specialty Area with 6 years (MD or equivalent) or equivalent experience, 10 years (PhD or Pharm
  
  D) or equivalent experience of involvement in clinical research or drug development in an industry environment spanning clinical activities in Phases I through III/IV, including…